Africa In Vitro Diagnostics Market by Product & Services, Technology (Immunoassay, PoC, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoC), Customer Type — Forecast to 2029

Africa In Vitro Diagnostics Market by Product & Services, Technology (Immunoassay, PoC, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoC), Customer Type — Forecast to 2029

Africa In Vitro Diagnostics Market by Product & Services, Technology (Immunoassay, Point of Care, Molecular Diagnostics, Coagulation), Application (Infectious Diseases, Diabetes, Oncology), Diagnostic Approach (Lab, OTC, PoC), Customer Type — Forecast to 2029

The Africa IVD market is expected to grow at a CAGR of 4.8% from 2022 to 2029 to reach $1.78 billion by 2029

Following a detailed secondary and primary research and an in-depth analysis of the market scenario, the report provides the key drivers, restraints, challenges, and opportunities in the Africa IVD market.

The high prevalence of infectious diseases, the rising burden of chronic diseases, the rising initiatives to support the healthcare sector, and the growing awareness about the importance of early disease diagnosis are the major drivers for the Africa IVD market. However, poor healthcare facilities and infrastructure in African countries are the major challenges to the market’s growth.

Based on product category, in 2022, the reagents, assays, and kits segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the frequent use of assays & kits in the detection of various chronic diseases coupled with the high burden of infectious diseases in African countries.

Based on technology, in 2022, the immunoassay segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the advantages of immunoassays, such as simplicity, high accuracy standards, high throughput capability, and inherent specificity.

Based on application, in 2022, the infectious diseases segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is primarily attributed to the high prevalence of infectious diseases such as COVID-19, dengue, HIV, and Chagas disease in the region and the rising initiatives to boost testing capabilities.

Based on diagnostic approach, in 2022, the laboratory testing segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the availability of several IVD tests and the higher accuracy offered by laboratory testing.

Based on customer type, in 2022, the hospital laboratories testing segment is expected to account for the largest share of the Africa IVD market. The large market share of this segment is attributed to the high demand for IVD diagnostics and the higher preference for hospitals as the primary center of care.

Based on geography, in 2022, South Africa is expected to account for the largest share of this market. The major share of this region is mainly attributed to the high burden of diseases, the rising geriatric population, the increasing initiatives to promote diagnostic testing, and continuous efforts to develop healthcare infrastructure and promote awareness.

The key companies operating in the Africa IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).

Scope of the Report:

Africa IVD Market, by Product Category

Reagents, Assays, and Kits
Instruments
Software & Services

Africa IVD Market, by Technology

Immunoassay
Whole Blood Glucose Monitoring
Point-of-Care Diagnostics
Clinical Chemistry
Molecular Diagnostics
Hematology
Coagulation & Hemostasis
Critical Care
Urinalysis
Other IVD Technologies

Note: Other technologies include microscopy, hybridization, and loop-mediated amplification.

Africa IVD Market, by Application

Infectious Diseases
Diabetes
Oncology
Endocrinology
Cardiology
Other Applications

Note: Other applications include nephrology, toxicology, gastroenterology, neonatal, genetic, and neurological disorders.

Africa IVD Market, by Diagnostic Approach

Laboratory Testing
Point-of-Care Testing
OTC/Self-testing

Africa IVD Market, by Customer Type

Hospital Labs
Private Labs
Home Care/Self Testing
Government
Other Customer Types

Note: Other customer types include long-term care facilities, academic & research institutes, ambulatory care centers, and transfusion laboratories

Africa IVD Market, by Country

South Africa
Egypt
Nigeria
Kenya
Algeria
Tanzania
Morocco
Tunisia
Rest of Africa

Africa IVD Market - Report Summary

Report Metrics	Details
Years Considered	2020 - 2029
Base Year	2021
Forecast Period	2022-2029
Page Count	161
Units Referenced	Value (USD Million/Billion)
Segments/Key Topics	Market by Product Category, Technology, Application, Diagnostic Approach, and Customer Type
Regions Covered	South Africa, Algeria, Nigeria, Kenya, Morocco, Tunisia, Tanzania, Egypt, and Rest of Africa
Key Companies Mentioned	Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Mindray Bio-Medical Electronics Co., Ltd (China), and Illumina, Inc. (U.S.).

FAQs About the Report

What is the focus of the Africa IVD market?

The Africa IVD market covers the market size & forecasts of the various IVD products (in terms of reagents; assays; and kits, instruments, and software & services) offered by key market players based on various technologies such as immunoassay, whole blood glucose monitoring, point of care, molecular diagnostics, clinical chemistry, hematology, coagulation & hemostasis, urinalysis, critical care, microscopy, hybridization, and loop-mediated amplification. The IVD products are used for diagnosing various medical conditions managing infectious diseases, diabetes, oncology, cardiology, endocrinology, nephrology, toxicology, gastroenterology, neonatal, genetic, and neurological disorders. The Africa IVD market covers various IVD products offered for laboratory testing, OTC/self-testing, point of care testing that are used in hospital labs, private labs, home care / self-testing, government, long-term care facilities, academic & research institutes, ambulatory care centers, and transfusion laboratories

What is the value of revenue generated from the IVD products across Africa? At what rate their demand expected to grow for the next 5-7 years?

The Africa IVD market is projected to reach $1.78 billion by 2029, at a CAGR of 4.8% during the forecast period.

Which product category is estimated to hold the major share of the market?

Based on product category, the reagents, assays, and kits segment accounted for the largest share of the Africa IVD market in 2022.

Which technology segment is estimated to hold the major share of the market?

Based on technology, the immunoassay segment accounted for the largest share of the Africa IVD market in 2022.

Which application segment of the market is projected to create more traction in the Africa IVD market?

Based on application, the oncology segment is estimated to show the fastest growth rate in the forecast period.

Which customer type segment is estimated to hold the major share of the market?

Based on customer type, the hospital laboratories testing segment accounted for the largest share of the Africa IVD market in 2022.

What are the key factors supporting the growth of this market?

Large prevalence of infectious diseases, rising burden of chronic diseases, and initiatives to support healthcare, and growing awareness regarding early disease diagnosis have been considered to have a positive impact on the Africa IVD market.

Who are the major players operating in the Africa IVD Market?

Some of the key companies operating in the Africa IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), bioMérieux SA (France), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and Illumina, Inc. (U.S.).